A First-Line Therapy for Renal Cell Carcinoma that can Increase Overall Survival when Compared with Sutent Would Earn a Higher Patient Share in the United States Than...( Pfizer's Axitinib Earns Decision Reso...),Health
Navigation Links
| HOME >> MEDICINE >> TECHNOLOGY |
A First-Line Therapy for Renal Cell Carcinoma that can Increase Overall Survival when Compared with Sutent Would Earn a Higher Patient Share in the United States Than in Europe
Date:2/26/2009
Pfizer's Axitinib Earns Decision Resources' Gold-Standard for Renal Cell Carcinoma in 2012, According to a New Report from Decision Resources
WALTHAM, Mass., Feb. 26 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a first-line therapy for metastatic renal cell carcinoma that can increase overall survival in comparison with Pfizer's Sutent would earn a 50 percent patient share in the United States and a 35 percent patient share in Europe, according to surveyed U.S. and European oncologists.
The new report entitled Renal Cell Carcinoma (Metastatic): Axitinib's Improvements in Overall Survival will Differentiate it from Current and Emerging Therapies finds that a therapy's effect on overall survival is the attribute that most influences surveyed oncologists' prescribing decisions in metastatic renal cell carcinoma. Clinical data and the opinions of interviewed thought leaders indicate that Pfizer's axitinib has advantages over Sutent in this attribute. Sutent, the market sales leading agent, was Decision Resources' proprietary clinical gold standard in 2008 for metastatic renal cell carcinoma.
Based on available data and expert opinion, axitinib will earn gold-standard status for metastatic renal cell carcinoma in 2012 through 2017, following its approval for the indication in 2011. Interviewed experts anticipate that axitinib, which has competitive advantages and has shown impressive Phase II survival data in the second-line setting, will be more effective than Sutent.
"In the second-line setting, axitinib has shown an increase in median overall survival in clinical trials," said Decision Resources Analyst Laila Siddique. "This median overall survival is slightly longer than the overall survival observed with Sutent in the first-line setting. Axitinib's data are particularly impressive becaus
'/>"/>
| SOURCE Decision Resources Copyright©2009 PR Newswire. All rights reserved |
Related medicine technology :
1. New Overall Survival Study Results Confirm Oral Xeloda(R) plus Oxaliplatin (XELOX) is Comparable to FOLFOX-4 for the First-Line Treatment of Advanced Colorectal Cancer
2. Zevalin(R) Following Short-Course Chemotherapy with CHOP + Rituximab (CHOP-R) Doubles Complete Remission Rate in First-Line Treatment of Follicular Non- Hodgkins Lymphoma
3. Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer
4. Poniard Announces Positive First-Line Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in Patients with Metastatic Hormone Refractory Prostate Cancer
5. Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer
6. Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkins Lymphoma
7. Independent Physician Surveys Show if Approved, MF101 Could Become First-Line Treatment for Menopause Symptoms
8. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
9. Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency
10. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
11. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
Post Your Comments:
(Date:11/25/2009)...ALTHAM, Mass., Nov. 25 According t...ority on medical technology market intelligence, t... devices will continue to see rapid growth over th...down. MRG,s US Markets for Trauma Devices 2010 ...dynamic over the next five years, with competitors...
(Date:11/25/2009)...EW YORK, Nov. 25 Reportlinker.com ...ilable in its catalogue: ,, Pain Management -...m/p0164220/Pain-Management---Global-Trends.html ,...rgence of pain management clinics, and the advent ...n the pain management market. Healthcare reforms a...
(Date:11/25/2009)...NGHAM, Mass. and SYDNEY, Nov. 25 /PRNewswire-First...TWR ; ASX: HIN), a leading innovator and provider ... technologies revolutionizing the treatment of adv...heduled to make an investor presentation at the 21...8:00 am EST on Wednesday, December 2, 2009. The co...
Breaking Medicine Technology:US Trauma Fixation Device Market Not Seeing Signs of Slowdown 2US Trauma Fixation Device Market Not Seeing Signs of Slowdown 3Reportlinker Adds Pain Management - Global Trends 2Reportlinker Adds Pain Management - Global Trends 3Reportlinker Adds Pain Management - Global Trends 4Reportlinker Adds Pain Management - Global Trends 5Reportlinker Adds Pain Management - Global Trends 6HeartWare to Present at 21st Annual Piper Jaffray Health Care Conference in New York City 2Studies Show Genetic Activity of Antioxidants 52308 1Studies Show Genetic Activity of Antioxidants 52308 2Studies Show Genetic Activity of Antioxidants 52308 3Winners of the C Everett Koop Health Project Award Announced 52305 1Winners of the C Everett Koop Health Project Award Announced 52305 2Five Eating Patterns That Worsen Stress 52303 1Five Eating Patterns That Worsen Stress 52303 2Five Eating Patterns That Worsen Stress 52303 3...ignificant antiviral activity in vivo, SAN DIEGO,...S ) announced preliminary data today from two stud...epatitis C virus (HCV) NS5B,polymerase, in a prima...hronically infected with HCV genotype 1b each rece...or four days. A rapid viral,load decline was seen ...
...al therapy in development for menopausal symptoms,... Company,today announced positive results from a p... treat postmenopausal women with vulvovaginal atro... Top line data show that the,multi-center, double-...ll,of its co-primary endpoints. The study was cond...
Other Medicine Technology:Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection 2Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection 3Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection 4QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome 2QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome 3(Date:11/26/2009).... 27 The diabetes population in th...5 years and annual medical spending on the disease...llion today, according to a study published in the... Changing Diabetes ® Program (NCDP), a progra...team from the University of Chicago. ,, Accordi...
(Date:11/26/2009)...n emotional rollercoaster, study finds , ...he fear factor meets the jubilant sports fan. ,...y those who root for the winning team -- enjoy the... match and victory was in doubt, producing feeling...s Thanksgiving weekend as you,re glued to the TV s...
(Date:11/26/2009)...ommunications announces a highly effective and unc...truggling to make an economic recovery. , ...fears is the type of challenge that could send ail... to Dr. David Benton, business growth expert and a... – The Rfactor Intensive . “Fear is...
(Date:11/25/2009)...Nov. 25 Onyx Pharmaceu... the company will host two investor events in Dece...2009 - 9:00 a.m. CT/10:00 a.m. ET ,, Principa...rrounding carfilzomib in relapsed and/or refractor...an Society of Hematology (ASH) Annual Meeting and ...
(Date:11/25/2009)...Newswire-USNewswire/--AnarticlebyJanetWoodcock,M.D...arch,titled"ADifficultBalance-PainManagement,DrugS...NewEnglandJournalofMedicine. ,, (Logo: http://w..., Inthearticle,WoodcockdiscussesFDAeffortstostrik...eeditandmanagingtherisksposedbyvariousanalgesics.A...
Breaking Medicine News(10 mins):Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 3Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 4Health News:Watching the Nail-Biting Big Game Hurts So Good 2Health News:Watching the Nail-Biting Big Game Hurts So Good 3Health News:Pharmacist Injects Cure for Ailing Businesses 2Health News:Onyx Pharmaceuticals Announces December 2009 Investor Events 2[1] Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows[0] Watching the Nail-Biting Big Game Hurts So Good[1] Pharmacist Injects Cure for Ailing Businesses [0] Onyx Pharmaceuticals Announces December 2009 Investor Events[1] FDA's Woodcock Discusses Pain Management and Drug Safety in Nov. 26, 2009 Issue of The New England Journal of Medicine
...te, new report finds , , THURSDAY, Feb. 5 ...onal health information isn,t adequately protected...ing to an Institute of Medicine report. , The Heal... Congress to approve the development of an entirel...
...ogy textbook edited by Dr. Jose Biller became the ...ention of strokes in young people. , Now, Stroke...y revised. In the Second Edition, the 14 original ...ity Chicago Stritch School of Medicine. , In the ...
... to Africa to Witness Firsthand the Devastating Ef...NATI, Feb. 5 Pampers(R), the world,s leading diap...orth America "One Pack = One Vaccine" campaign to ...roviding life-saving vaccines to help protect preg...
.... (Nasdaq: HMSY ) today announced it will host a... February 20, 2009 to discuss the financial result...ich ended December 31. Financial results are sched...Lucia, President and COO, Walter Ho...
... University of Texas M. D. Anderson Cancer Center ...essel formation, and vascular endothelial growth f... in women with sex cord-stromal ovarian tumors. Th... ovarian tumors are rare, accounting for five to s...
...hen H. Schneider, Ph.D.,professor of Environmental... , a,climatologist and cancer survivor who shared ...ent Al Gore, will be the keynote speaker at the fo...y,settings, where 84% percent of the cancer care i...
Other Medicine News:Health News:Private Health Care Info Needs Better Safeguards 2Health News:Landmark textbook on strokes in children and young adults updated in second edition 2Health News:Video: Pampers Together with Actress Salma Hayek Helps UNICEF Move Closer Toward Goal of Eliminating Deadly Tetanus Through Global 'One Pack = One Vaccine' Campaign 2Health News:Video: Pampers Together with Actress Salma Hayek Helps UNICEF Move Closer Toward Goal of Eliminating Deadly Tetanus Through Global 'One Pack = One Vaccine' Campaign 3Health News:Video: Pampers Together with Actress Salma Hayek Helps UNICEF Move Closer Toward Goal of Eliminating Deadly Tetanus Through Global 'One Pack = One Vaccine' Campaign 4Health News:Video: Pampers Together with Actress Salma Hayek Helps UNICEF Move Closer Toward Goal of Eliminating Deadly Tetanus Through Global 'One Pack = One Vaccine' Campaign 5Health News:Video: Pampers Together with Actress Salma Hayek Helps UNICEF Move Closer Toward Goal of Eliminating Deadly Tetanus Through Global 'One Pack = One Vaccine' Campaign 6Health News:HMS Holdings Corp. Hosts Fourth Quarter and Full Year 2008 Financial Teleconference and Presentation 2Health News:Angiogenesis linked to poor survival in patients with rare type of ovarian cancer 2Health News:Nobel Peace Prize Winner Stephen Schneider Keynotes Annual Conference of Community Oncologists 2Health News:Nobel Peace Prize Winner Stephen Schneider Keynotes Annual Conference of Community Oncologists 3Health News:Nobel Peace Prize Winner Stephen Schneider Keynotes Annual Conference of Community Oncologists 4Private Health Care Info Needs Better SafeguardsLandmark textbook on strokes in children and young adults updated in second editionVideo: Pampers Together with Actress Salma Hayek Helps UNICEF Move Closer Toward Goal of Eliminating Deadly Tetanus Through Global 'One Pack = One Vaccine' CampaignHMS Holdings Corp. Hosts Fourth Quarter and Full Year 2008 Financial Teleconference and PresentationAngiogenesis linked to poor survival in patients with rare type of ovarian cancerNobel Peace Prize Winner Stephen Schneider Keynotes Annual Conference of Community Oncologists
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |